Grufity logoGrufity logo

Catalyst Pharmaceuticals Inc Stock Research

CPRX

16.58USD+0.12(+0.73%)Market Closed

Market Summary

USD16.58+0.12
Market Closed
0.73%

CPRX Alerts

CPRX Stock Price

CPRX RSI Chart

CPRX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

21.01

Price/Sales (Trailing)

8.15

EV/EBITDA

13.8

Price/Free Cashflow

15.04

CPRX Price/Sales (Trailing)

CPRX Profitability

EBT Margin

44.08%

Return on Equity

24.78%

Return on Assets

20.09%

Free Cashflow Yield

6.65%

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

214.2M

Revenue Y/Y

58.6%

Revenue Q/Q

6.14%

CPRX Earnings

Earnings (TTM)

83.1M

Earnings Y/Y

173.62%

Earnings Q/Q

11.97%

Price Action

52 Week Range

6.1522.11
(Low)(High)

Last 7 days

2.9%

Last 30 days

7.2%

Last 90 days

-10.9%

Trailing 12 Months

100%

CPRX Financial Health

Current Ratio

6.18

CPRX Investor Care

Shares Dilution (1Y)

2.20%

Diluted EPS (TTM)

0.75

Peers (Alternatives to Catalyst Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
292.3B
1.4B
-8.63% 14.28%
-145.87
206.43
20.37% -37.45%
282.2B
58.1B
2.64% 1.09%
23.85
4.86
3.30% 2.55%
87.8B
12.2B
6.65% 17.65%
20.25
7.22
-24.26% -46.28%
81.0B
8.9B
8.19% 20.73%
24.38
9.07
17.91% 41.84%
24.8B
1.0B
2.52% 22.68%
-21.95
23.93
22.88% -32.64%
12.1B
933.0M
-5.36% 76.43%
-17.23
12.99
32.93% -67.99%
10.3B
1.9B
-8.55% 24.83%
14.17
5.32
14.88% 52.86%
MID-CAP
4.4B
504.0K
-13.23% 146.90%
-14.85
2.5K
-66.53% -22.12%
2.8B
363.3M
-12.16% -44.78%
-3.98
7.75
3.39% -55.81%
2.7B
204.0M
4.26% -29.57%
-4.84
13.22
13.30% 13.44%
2.2B
12.4M
-17.27% -54.78%
-2.9
172.97
- -27.34%
SMALL-CAP
1.7B
214.2M
7.24% 100.00%
21.01
8.15
52.10% 110.42%
442.4M
151.9M
15.09% -18.62%
-3.69
2.91
96.19% 40.75%
30.3M
-
159.64% 1267.83%
-0.72
19.11
-77.61% 7.22%
3.3M
94.6M
-18.37% -4.40%
-0.01
0.03
34.30% -80.65%

Financials for Catalyst Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue11.7%214192170154141
Operating Expenses4.1%11210898.0094.0088.00
  S&GA Expenses2.5%58.0057.0055.0053.0050.00
  R&D Expenses-4.3%20.0021.0017.0017.0017.00
EBITDA16.4%85.0073.0060.0053.00-
EBITDA Margin3.5%0.44*0.43*0.39*0.38*-
Earnings Before Taxes23.9%10585.0073.0060.0053.00
EBT Margin3.5%0.44*0.43*0.39*0.37*-
Net Income24.2%83.0067.0054.0045.0039.00
Net Income Margin9.2%0.35*0.32*0.29*0.28*-
Free Cahsflow26.2%95.0075.0064.0059.00-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets12.8%376333267247238
  Current Assets16.1%321276243221210
    Cash Equivalents16.5%298256211178171
  Inventory-4.6%7.007.008.008.008.00
  Net PPE-4.0%1.001.001.001.001.00
Liabilities19.2%75.0063.0026.0027.0031.00
  Current Liabilities28.9%58.0045.0022.0023.0027.00
Shareholder's Equity11.3%300270241220207
  Retained Earnings104.4%50.0024.002.00-15.62-26.31
  Additional Paid-In Capital2.0%250246239236233
Accumulated Depreciation10.4%0.000.000.000.00-
Shares Outstanding1.2%105104103103103
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations22.0%11695.0076.0065.0060.00
  Share Based Compensation6.1%8.007.007.006.006.00
Cashflow From Investing2761.6%9.00-0.35-0.22-11.02-
Cashflow From Financing154.9%2.00-3.08-9.17-9.88-8.14
  Buy Backs-31.0%7.0010.0015.0014.0012.00

Risks for CPRX

What is the probability of a big loss on CPRX?

90.8%


Probability that Catalyst Pharmaceuticals stock will be more than 20% underwater in next one year

67.7%


Probability that Catalyst Pharmaceuticals stock will be more than 30% underwater in next one year.

65.4%


Probability that Catalyst Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CPRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalyst Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for CPRX

Cumulative Returns on CPRX

43.0%


10-Year Cumulative Returns

45.5%


7-Year Cumulative Returns

47.3%


5-Year Cumulative Returns

62.7%


3-Year Cumulative Returns

What are the long-term rolling returns for CPRX?

FIve years rolling returns for Catalyst Pharmaceuticals.

Annualized Returns

Which funds bought or sold CPRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
reduced
-4.92
257,806
939,002
0.01%
2023-03-15
B. Riley Wealth Advisors, Inc.
new
-
475,583
475,583
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-19.96
753,423
5,448,420
0.01%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-25.00
-
5,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-4.28
292,463
1,048,460
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
172,000
555,000
0.01%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-2,424,000
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
12,500
4,687
4,687
-%
2023-02-16
GHP Investment Advisors, Inc.
unchanged
-
7,320
22,320
-%
2023-02-15
Steward Partners Investment Advisory, LLC
unchanged
-
488
1,488
-%

1–10 of 46

Latest Funds Activity

Are funds buying CPRX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CPRX
No. of Funds

Catalyst Pharmaceuticals News

MarketBeat

Zacks Research Comments on Catalyst Pharmaceuticals, Inc.'s ....

MarketBeat,
112 minutes ago

Seeking Alpha

3 Defensive Stocks for 2023.

Seeking Alpha,
27 hours ago

Investor's Business Daily

ABNB Stock Leads 11 Stocks Eyeing 53% To 667% Growth.

Investor's Business Daily,
41 hours ago

Schedule 13G FIlings of Catalyst Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
armistice capital, llc
0%
0
SC 13G/A
Feb 10, 2023
flynn james e
5.65%
5,884,448
SC 13G/A
Feb 09, 2023
vanguard group inc
6.50%
6,768,741
SC 13G
Feb 08, 2023
state street corp
7.57%
7,873,314
SC 13G/A
Jan 26, 2023
blackrock inc.
15.1%
15,690,326
SC 13G/A
Jan 20, 2023
blackrock inc.
15.1%
15,690,326
SC 13G/A
Nov 14, 2022
flynn james e
5.82%
6,060,491
SC 13G
Feb 15, 2022
armistice capital, llc
9.3%
9,572,000
SC 13G/A
Feb 09, 2022
vanguard group inc
4.69%
4,836,313
SC 13G/A
Feb 09, 2022
state street corp
4.90%
5,050,989
SC 13G/A

CPRX Fair Value

Catalyst Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Catalyst Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

19.69

18.76%

25.51

53.86%

49.11

196.20%

79.84

381.54%

135.24

715.68%
Current Inflation

18.07

8.99%

23.05

39.02%

43.34

161.40%

69.43

318.76%

116.42

602.17%
Very High Inflation

16.05

-3.20%

20.07

21.05%

36.50

120.14%

57.28

245.48%

94.69

471.11%

Historical Catalyst Pharmaceuticals Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Catalyst Pharmaceuticals

View All Filings
Date Filed Form Type Document
Mar 31, 2023
8-K
Current Report
Mar 30, 2023
4
Insider Trading
Mar 30, 2023
4
Insider Trading
Mar 24, 2023
4
Insider Trading
Mar 22, 2023
4
Insider Trading
Mar 15, 2023
10-K
Annual Report
Mar 15, 2023
8-K
Current Report
Mar 07, 2023
8-K
Current Report
Feb 17, 2023
4
Insider Trading
Feb 17, 2023
4
Insider Trading

Latest Insider Trading transactions for CPRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-29
Del Carmen Jeffrey
acquired
127,063
3.17659
40,000
chief commercial officer
2023-03-29
Del Carmen Jeffrey
sold
-667,810
16.6952
-40,000
chief commercial officer
2023-03-29
GRANDE ALICIA
sold
-835,100
16.702
-50,000
vp, treasurer and cfo
2023-03-29
GRANDE ALICIA
acquired
56,500
1.13
50,000
vp, treasurer and cfo
2023-03-28
GRANDE ALICIA
acquired
45,990
0.79
58,216
vp, treasurer and cfo
2023-03-28
GRANDE ALICIA
sold
-962,786
16.5382
-58,216
vp, treasurer and cfo
2023-03-22
GRANDE ALICIA
sold
-689,528
16.5022
-41,784
vp, treasurer and cfo
2023-03-22
GRANDE ALICIA
acquired
33,009
0.79
41,784
vp, treasurer and cfo
2023-03-20
Elsbernd Brian
sold
-803,450
16.069
-50,000
chief compliance/legal officer
2023-03-20
Elsbernd Brian
acquired
56,500
1.13
50,000
chief compliance/legal officer

1–10 of 50

Patrick J. McEnany
80
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Total revenues$ 214,203$ 140,833$ 119,073
Operating costs and expenses:   
Cost of sales34,39321,88417,039
Research and development19,78916,93616,497
Selling, general and administrative58,18349,62844,234
Total operating costs and expenses112,36588,44877,770
Operating income101,83852,38541,303
Other income, net2,881282587
Net income before income taxes104,71952,66741,890
Income tax provision (benefit)21,64013,185(33,093)
Net income$ 83,079$ 39,482$ 74,983
Net income per share:   
Basic$ 0.8$ 0.38$ 0.72
Diluted$ 0.75$ 0.37$ 0.71
Weighted average shares outstanding:   
Basic103,374,606103,379,349103,512,913
Diluted111,375,631107,795,585106,242,273
Net income$ 83,079$ 39,482$ 74,983
Other comprehensive income:   
Unrealized gain (loss) on available-for-sale securities, net of tax of ($54), $46 and $0, respectively172(179)22
Comprehensive income83,25139,30375,005
Product revenue, net [Member]   
Revenues:   
Total revenues213,938137,997118,790
License and other revenue [Member]   
Revenues:   
Total revenues$ 265$ 2,836$ 283

CPRX Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 298,395$ 171,445
Short-term investments019,821
Accounts receivable, net10,4396,619
Inventory6,8057,870
Prepaid expenses and other current assets5,1584,351
Total current assets320,797210,106
Operating lease right-of-use asset2,7703,017
Property and equipment, net847959
License and acquired intangibles, net32,471 
Deferred tax assets, net18,73623,697
Deposits99
Total assets375,630237,788
Current Liabilities:  
Accounts payable3,9752,768
Accrued expenses and other liabilities53,61324,295
Total current liabilities57,58827,063
Operating lease liability, net of current portion3,5573,894
Other non-current liabilities14,064 
Total liabilities75,20930,957
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2022 and 202100
Common stock, $0.001 par value, 200,000,000 shares authorized; 105,263,031 shares and 102,992,913 shares issued and outstanding at December 31, 2022 and 2021, respectively105103
Additional paid-in capital250,430233,186
Retained earnings (accumulated deficit)49,862(26,310)
Accumulated other comprehensive income (loss)24(148)
Total stockholders' equity300,421206,831
Total liabilities and stockholders' equity$ 375,630$ 237,788